Reference is made to the stock exchange notice published on 22 June 2018 regarding a private placement with gross proceeds of approximately NOK 123.2 million (the " Private Placement ") and the stock exchange notice published on 19 June 2018 regarding a contemplated repair issue following the Private Placement (the " Subsequent Offering "). The general meeting of Hofseth BioCare ASA (" HBC " or the " Company ") resolved the share capital increases related to the Private Placement and the Subsequent Offering on 16 July 2018.
The Financial Supervisory Authority of Norway has on 23 August 2018 approved a prospectus prepared by the Company (the " Prospectus ") in connection with the listing of the new shares issued in the Private Placement and the offering and listing of offer shares in the Subsequent Offering.
The shares issued in the Private Placement, currently registered on a separate ISIN, will as a consequence be transferred to the ordinary ISIN of the Company as of today.
The Prospectus is available at the website of Sparebank 1 Markets (the " Manager "), www.sb1markets.no , and the website of the Company, www.hofsethbiocare.com .
The Subsequent Offering comprises an issuance of up to 8,888,889 new shares in the Company (the " Offer Shares "), each with a par value of NOK 1, and at a subscription price of NOK 2.25 per Offer Share.
The Subsequent Offering will be directed towards Eligible Shareholders, being the Company's shareholders as of 18 June 2018, as registered in the VPS on 20 June 2018, except (i) shareholders who participated in the Private Placement, and (ii) shareholders who are resident in a jurisdiction where such offering would be unlawful or would require any filing, registration or similar action (other than a prospectus in Norway).
The Eligible Shareholders will be granted 0.1616 non-tradable subscription rights (" Subscription Rights ") per share held as of 18 June 2018, as registered in the VPS on 20 June 2018. Each Subscription Right will give a preferential right to subscribe for and be allocated one Offer Share. The number of Subscription Rights issued to each Eligible Shareholder will be rounded down to the nearest whole number of Subscription Rights. Oversubscription will be allowed. Subscription without Subscription Rights will not be allowed.
The subscription period in the Subsequent Offering commences on 27 August 2018 at 09.00 hours and expires on 10 September 2018 at 16.30 hours.
Further information about the Subsequent Offering is available in the Prospectus.
For further information, please contact: Jon Olav Ødegård, CFO of Hofseth BioCare ASA Mob: +47 936 32 966 E-mail: joo@hofsethbiocare.no
About Hofseth BioCare ASA: HBC is a Norwegian biotech company that offers high-value ingredients and finished products for humans and pets. The company is founded on the core values of sustainability, traceability and optimal utilization of natural resources. Through an innovative hydrolysis technology, HBC is able to preserve the quality of salmon oil, proteins and calcium, prepared of fresh salmon off-cuts. HBC's objective is to contribute to the efficient use of marine resources and deliver quality products for ingredients and finished consumer products in the nutrition market.
Hofseth BioCare's headquarters are located in Ålesund, Norway with branches in Oslo, Chicago, Mumbai and Tokyo. HBC is listed on Oslo Stock Exchange Axess list with ticker "HBC". More information about Hofseth BioCare at www.hofsethbiocare.com and www.facebook.com/hofsethbiocare This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
